Are Medicare's New Quality Incentives Large Enough To Change Hospital Behavior?

The ACCESS Model signals a shift toward outcome-aligned payments and a necessary reframing of what “value” actually means.

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

France approved botensilimab plus balstilimab for select ovarian cancers and soft tissue sarcomas, expanding early access to this dual immunotherapy.

Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.

Jose Guzman Garcia, PharmD, MHA, BCCCP, discusses key pharmacy initiatives at UC Davis Health.

With ACA subsidies in limbo, ICHRAs may reshape how Americans access coverage. Here are 5 FAQs explaining what they are, who benefits, and key trade-offs.